Volume 21, Issue 4 2300195
RESEARCH ARTICLE

Safety and efficacy of plasma-activated water on prolonged viral shedding of COVID-19 patients: A randomized controlled trial

Xiaoya Guo

Xiaoya Guo

Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China

Search for more papers by this author
Xing Lv

Xing Lv

Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China

Search for more papers by this author
Yunfu Wu

Yunfu Wu

Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China

Search for more papers by this author
Mingming Wang

Mingming Wang

Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China

Search for more papers by this author
Shuo Wu

Shuo Wu

Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China

Search for more papers by this author
Li Guo

Li Guo

State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an, China

Search for more papers by this author
Zifeng Wang

Zifeng Wang

State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an, China

Search for more papers by this author
Zhihong Shi

Zhihong Shi

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Search for more papers by this author
Rui Huang

Rui Huang

Department of Gastroenterology, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, China

Search for more papers by this author
Hua Zhang

Hua Zhang

Department of Pulmonary and Critical Care Medicine, Baoji Central Hospital, Baoji, China

Search for more papers by this author
Xiaona Niu

Xiaona Niu

Department of Cardiology, Tangdu Hospital, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China

Search for more papers by this author
Mingzhe Rong

Mingzhe Rong

State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an, China

Search for more papers by this author
Liqiang Song

Corresponding Author

Liqiang Song

Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China

Correspondence Liqiang Song, Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an 710032, China.

Email: [email protected]

Dingxin Liu, State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an 710049, China.

Email: [email protected]

Search for more papers by this author
Dingxin Liu

Corresponding Author

Dingxin Liu

State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an, China

Correspondence Liqiang Song, Department of Respiratory and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an 710032, China.

Email: [email protected]

Dingxin Liu, State Key Laboratory of Electrical Insulation and Power Equipment, Center for Plasma Biomedicine, Xi'an Jiaotong University, Xi'an 710049, China.

Email: [email protected]

Search for more papers by this author
First published: 20 December 2023
Citations: 2

Xiaoya Guo and Xing Lv contributed equally to this study.

This study is registered with the Chinese Clinical Trials Registry (Registration No. ChiCTR2200056562).

Abstract

Shortening the duration of the viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to controlling viral transmission, alleviating the burden on the healthcare system, and ultimately mitigating the impact of the pandemic. This randomized, single-blind, placebo-controlled clinical trial aimed to investigate the safety and efficacy of gargling with plasma-activated water (PAW) on prolonged viral shedding in patients infected with SARS-CoV-2 Delta and Omicron variants. Sixty-two subjects, aged 18–80 years and infected with SARS-CoV-2, were recruited at two coronavirus disease 2019 (COVID-19)-designated hospitals in Shaanxi from January to March 2022. Primary outcomes included cumulative conversion rates, incidence of adverse reactions, and biosafety parameters. Results suggested that PAW gargling treatment might contribute to reducing the duration of SARS-CoV-2 Delta and Omicron variant infections and alleviating symptoms.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.